Agri Business

Biovet to invest ₹ 200 cr for Malur plant expansion

Our Bureau Hyderabad | Updated on June 21, 2019

Expansion of FMD vaccine facilities to help deliver 200 million doses

Biovet, the animal vaccine maker will invest ₹ 200 crore as part of its expansion plans to meet the growing market demands, especially the one to tackle Foot & Mouth Disease (FMD) and Brucellosis in animals.

It has commenced the work towards expanding the FMD vaccine manufacturing facility in Malur, Karnataka. Announcing the plans, Krishna Ella, Promoter of Biovet said “Expansion of our FMD vaccine facilities to deliver 200 million doses is an important step to increase our contribution to meet the shortage of this vaccine in the country”.

The company, based in Bengaluru will construct a new Brucella Vaccine Production facility at the Malur site to produce 100 million doses. It will make Biovet the world’s largest manufacturer of this vaccine, he said.

The Centre has been laying emphasis on animal health with a greater focus on eradicating FMD.

According to estimates, India’s FMD control programme requires 1,000 million doses every year, whereas the current production capacity manufactured in the country is only around 500 million doses. There is an unmet need for 500 million doses, and Biovet aims to fulfil this gap through the planned expansion.

Established in 2006, Biovet has several new products in the pipeline. It has license to produce,:· HemorrhagicSepticaemia vaccine for cattle and buffaloes ;Enterotoxaemia vaccine for sheep and goats; · Black quarter vaccine for cattle and buffaloes.

The company said its investments would provide jobs in construction and create "new employment opportunities" in Malur as well as benefiting farmers.

Published on June 21, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor